Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity

Oncogene volume 22, pages 2739–2749 (2003)Cite this article

Abstract

The expression of cutaneous fatty acid-binding protein (C-FABP) in prostate tissues was examined by immunohistochemistry. Among the 76 cases, all seven (100%) normal tissues were unstained. Of the 35 benign prostatic hyperplasia (BPH), 25 (71.4%) specimens were unstained and 10 (28.6%) were stained positively. For the 34 prostatic carcinomas, the C-FABP expression was remarkably increased: 25 (73.5%) samples stained positively, and only nine (26.5%) were unstained. Transfection of a vector expressing an antisense C-FABP transcript into the PC-3M prostatic cancer cells yielded two transfectant lines: PC-3M-CFABP-1 and PC-3M-CFABP-3, producing, respectively, a 3.8- and a 6.9-fold reduction in C-FABP levels. Comparing with the control transfectants, the in vitro invasiveness of both PC-3M-CFABP-1 and PC-3M-CFABP-3 was significantly reduced. When tested in nude mouse, the average size of tumours produced by PC-3M-CFABP-1 and by PC-3M-CFABP-3 was reduced by 2.9- and 4.2-fold respectively, in comparison with that of tumours produced by the control transfectants. Analysis showed that the decreased vascular endothelial growth factor (VEGF) and microvessel densities in the tumours were associated with the reduced C-FABP. These data show that C-FABP is increased in prostatic carcinoma cells and suppression of its expression can significantly inhibit the tumorigenicity, probably by reducing the expression of VEGF.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and Mcewan RNA . (1987). Cancer Res., 47, 3239–3245.

  • Bass NM . (1988). Int. Rev. Cytol., 111, 143–184.

  • Celis JE, Østergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Ørntoft TF and Rasmussen HH . (1996). Cancer Res., 56, 4782–4790.

  • Celis A Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, Hein B, Ostergaard M, Wolf H, Orntoft T and Celis JE . (1999). Electrophoresis, 20, 355–361.

  • Chen HJ, Ke YQ, Oates AJ, Barraclough R and Rudland PS . (1997). Oncogene, 14, 1581–1588.

  • Chen HJ, Treweeke AT, Ke YQ, West DC and Toh CH . (2000). Br. J. Cancer, 82, 1694–1710.

  • Deshmukh N, Scotson J, Dodson AR, Smith P, Ke YQ and Foster CS . (1997). Br. J. Urol., 80, 869–874.

  • Foster CS, Cornford P, Forsyth L, Djamgoz MBA and Ke YQ . (1999). Br. J. Urol., 83, 171–194.

  • Foster CS, Dodson A, Karavana V, Smith P and Ke YQ . (2002). J. Pathol., 197, 551–565.

  • Glatz JFC and VanderVusse GJ . (1997). Prostaglandins Leukot. Essent. Fatty Acids, 57, 1–10.

  • Gleason DF, Mellinger GT and the Veterans Administration Co-operative Urology Research Group. (1972). J. Urol., 111, 58–64.

  • Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Horsfall DJ and Tilley WD . (2002). Cancer Res., 62, 854–859.

  • Janik P, Briand P and Hartmann NR . (1975). Cancer Res., 35, 3698–3704.

  • Jing C, Abd-Elghany MI, Beesley C, Foster CS, Rudland PS, Smith P and Ke YQ . (2002). J. Natl. Cancer Inst., 94, 482–490.

  • Jing C, Beesley C, Foster CS, Chen H, Rudland PS, West DC, Fujii H, Smith PS and Ke YQ . (2001). Cancer Res., 61, 4357–4364.

  • Jing C, Beesley C, Foster CS, Rudland PS, Fujii H, Chen HJ, Smith P and Ke YQ . (2000a). Cancer Res., 60, 2390–2398.

  • Jing C, Rudland PS, Foster CS and Ke YQ . (2000b). Anal. Biochem., 287, 334–337.

  • Kaighn ME, Lechner JF, Narayan KS and Jones LW . (1978). Natl. Cancer Inst. Monogr., 49, 17–21.

  • Ke YQ, Beesley C, Smith P, Barraclough B, Rudland PS and Foster CS . (1998). Br. J. Cancer, 77, 287–296.

  • Ke YQ, Fernig DG, Wilkinson MC, Smith JA, Rudland PS and Barraclough BR . (1993). J. Cell Sci., 106, 135–143.

  • Ke YQ, Jing C, Barraclough R, Smith P, Davies MPA and Foster CS . (1997). Int. J. Cancer, 71, 832–837.

  • Ke YQ, Jing C, Rudland PS, Smith P and Foster CS . (1999a). Nucleic Acids Res., 27, 912–914.

  • Ke YQ, Rudland PS, Jing C, Smith PH and Foster CS . (1999b). Anal. Biochem., 269, 201–204.

  • Kozlowski JM, Fidler JJ, Campbell D, Xu ZL, Kaighn ME and Hart IR . (1984). Cancer Res., 44, 3522–3529.

  • Landis SH, Murray T, Bolden S and Wingo PA . (1999). CA: Cancer J. Clin., 41, 8–31.

  • Lefebvre AM, Chen IH, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R and Auwerx J . (1998). Nat. Med., 4, 1053–1057.

  • Liang P and Pardee AB . (1992). Science, 257, 967–971.

  • Madsen P, Rasmussen HH, Leffers H, Honoré B and Celis JE . (1992). J. Invest. Dermatol., 99, 299–305.

  • Masood R, Cai J, Zhen T, Smith DL, Hinton DR and Gill PS . (2001). Blood, 98, 1904–1913.

  • Masouye I, Hagens G, VanKuppevelt TH, Madsen P, Saurat JH, Veerkamp JH, Pepper MS and Siegenthaler G . (1997). Circ. Res., 81, 297–303.

  • Østergaard M, Rasmussen HH, Nielsen HV, Vorum H, Ørntoft TF, Wolf H and Celis JE . (1997). Cancer Res., 57, 4111–4117.

  • Saez E, Tontonoz P, Nelson MC, Alvarez JGA, U TM and Baird SM . (1998). Nat. Med., 4, 1058–1061.

  • Sinha P, Hütter G, Köttgen E, Dietel M, Schadendorf D and Lage H . (1999). Electrophoresis, 20, 2952–2960.

  • Smith P, Rhodes NP, Ke YQ and Foster CS . (1998). FEBS Lett., 423, 19–24.

  • Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A and Freeman MR . (2001). Am. J. Pathol., 159, 651–659.

  • Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF . (1978). Int. J. Cancer, 21, 274–281.

  • Storch J and Bass NM . (1990). J. Biol. Chem., 265, 7827–7831.

  • Veikkola T, Karkkainen M, Claesson-Welsh L and Alitalo K . (2001). Cancer Res., 60, 203–212.

  • Wagner RW . (1994). Nature, 372, 333–335.

  • Watanabe R, Fujji H, Yamamoto A, Hashimoto T, Kameda K, Ito M and Ono T . (1997). J. Dermatol. Sci., 16, 17–22.

  • Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA and Milburn MV . (1999). Mol. Cell, 3, 397–403.

  • Yamakawa K, Hosoi M, Koyama H, Tanaka S, Fukumoto S, Morii H and Nishizawa Y . (2000). Biochem. Biophys. Res. Commun., 271, 571–574.

Download references

Acknowledgements

This work was supported by research grants from the Wellcome Trust and from North West Cancer Research Fund.

Author information

Authors and Affiliations

  1. Department of Pathology, Molecular Pathology Laboratory, Faculty of Medicine, University of Liverpool, Liverpool, L69 3BX, UK

    Janet Adamson, Elwin A Morgan, Carol Beesley, Yongqiang Mei, Christopher S Foster, Paul H Smith & Youqiang Ke

  2. Department of Biochemistry, Niigata University School of Medicine, Niigata 951, Japan

    Hiroshi Fujii

  3. School of Biological Sciences, University of Liverpool, Liverpool, L69 3BX, UK

    Philip S Rudland

Authors
  1. Janet Adamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elwin A Morgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carol Beesley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yongqiang Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher S Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philip S Rudland
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paul H Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Youqiang Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Youqiang Ke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adamson, J., Morgan, E., Beesley, C. et al. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene 22, 2739–2749 (2003). https://doi.org/10.1038/sj.onc.1206341

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206341

Keywords

This article is cited by

Search

Advanced search

Quick links